Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Alva

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Pigment Cell & Melanoma Research|October 31, 2020
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanomaVincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003Arkadiusz Z Dudek, Li C Liu, Shilpa Gupta, et al.
Investigational New Drugs|November 6, 2018
Pazopanib with low fat meal (PALM) in advanced renal cell carcinomaMelissa A Reimers, Maryann M Shango, Stephanie Daignault-Newton, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 18, 2016
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With ChemotherapyJorge D Ramos, Martin F Casey, Aristotelis Bamias, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
British Journal of Cancer|October 9, 2018
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapyTracy L Rose, David D Chism, Ajjai S Alva, et al.
European Urology|July 8, 2018
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell CarcinomaAaron M Udager, Andrew S McDaniel, Daniel H Hovelson, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Plos One|April 11, 2015
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancerJean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Pigment Cell & Melanoma Research|October 31, 2020
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanomaVincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003Arkadiusz Z Dudek, Li C Liu, Shilpa Gupta, et al.
Investigational New Drugs|November 6, 2018
Pazopanib with low fat meal (PALM) in advanced renal cell carcinomaMelissa A Reimers, Maryann M Shango, Stephanie Daignault-Newton, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 18, 2016
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With ChemotherapyJorge D Ramos, Martin F Casey, Aristotelis Bamias, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
British Journal of Cancer|October 9, 2018
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapyTracy L Rose, David D Chism, Ajjai S Alva, et al.
European Urology|July 8, 2018
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell CarcinomaAaron M Udager, Andrew S McDaniel, Daniel H Hovelson, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Plos One|April 11, 2015
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancerJean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Pageof 8